Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08SYN
|
||||
| Former ID |
DNC014419
|
||||
| Drug Name |
3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H12FN3O
|
||||
| Canonical SMILES |
CCC1=NC(=CC=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
|
||||
| InChI |
1S/C15H12FN3O/c1-2-13-4-3-5-14(18-13)19-15(20)11-6-10(9-17)7-12(16)8-11/h3-8H,2H2,1H3,(H,18,19,20)
|
||||
| InChIKey |
LBPUNEZWEHBQQO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Metabotropic glutamate receptor 5 | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Long-term potentiation | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Huntington's disease | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group I pathway | |||||
| Endogenous cannabinoid signaling | |||||
| Reactome | G alpha (q) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| GPCRs, Class C Metabotropic glutamate, pheromone | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. Epub 2010 Jun 15.3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds withCNS exposure in rats. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.